Introduction {#s1}
============

Functional dyspepsia (FD) is the pain or discomfort of the upper digestive tract without organic pathology that readily explains symptoms (Tack and Talley, [@B65]; Talley, [@B67]). The prevalence of FD in the general population is as high as 12--15% (El-Serag and Talley, [@B20]; Talley, [@B67]), and it significantly affects our moods and reduces the quality of life (Brun and Kuo, [@B6]). Treatments of FD involves eradication of *Helicobacter pylori* (Mokhtare et al., [@B50]), acid inhibition with proton pump inhibitors, tricyclic antidepressants (Ford et al., [@B21]), and prokinetic drugs (Quigley, [@B55]). Unfortunately, meta-analyses emphasized that these medications are still unsatisfactory for promoting the symptoms of FD, and the efficacy of currently available treatments be limited (Vakil et al., [@B70]). Clinical reports indicate that the safety and effectiveness of the Zhi-zhu Wan (ZZW) in the treatment of FD are remarkable.

ZZW is composed of two herbs, Zhishi (the immature fruit of *Citrus aurantium* L. or *Citrus sinensis* Osbeck) and Baizhu (the roots of *Atractylodes macrocephala* Koidz), which has prominence effect with FD (Wang et al., [@B73]; Xia et al., [@B79]), and their promotion of the gastrointestinal peristalsis activity has been confirmed in animal experiments (Liu, [@B40]; Huang et al., [@B26]; Chen J. et al., [@B10]). Baizhu showed the bidirectional regulation effects on gastrointestinal that might be related to the level of vasoactive intestinal peptide (VIP) and p substance (SP) (Chen J. et al., [@B10]). The combination of Zhishi and Baizhu may exert its therapeutic effects on FD by regulating the function of M and D endocrine cell, increasing the expression of acetylcholine and nitrogen monoxide, and regulating the gene expression of gut hormone receptor (Liu, [@B40]).

In pharmacokinetic studies, the pharmacokinetics and pharmacodynamics characteristics of ZZW after oral administration indicated that hesperidin and naringenin might be destroyed in the intestinal tract, metabolized by intestinal microflora, and excreted from bile or urine (Sun et al., [@B63]). In pharmacologic studies, flavonoids in Zhishi have a dose-dependent diastolic effect on pyloric circular smooth muscle strips in rats. These studies confirmed that the Zhishi and Baizhu could be beneficial in the treatment of patients with FD. Nevertheless, there is no literature expounds the underlying therapeutic mechanism of ZZW so far.

Considering the flaws of traditional experimental methods its approaches are difficult to reveal the co-module association mechanism of herb-component-gene-disease due to the "multi-component" and "multi-target" features of the TCM systems. Systemic pharmacology is an effective tool to elucidate the synergistic and potential mechanisms of the networks between component-target and target-disease, it provides a new perspective on the therapeutic mechanisms of TCM. Recently, several system pharmacology models were used to decode the underlying mechanism of herb pair (Cheng S. P. et al., [@B11]; Zhang et al., [@B84]; Yue et al., [@B82]) and Chinese formulae (Zhang et al., [@B85]), but most of them losts the synergistic information.

Currently, a novel system pharmacology model is developed to explore the therapeutic mechanism of ZZW in the treatment of FD (Figure [1](#F1){ref-type="fig"}), integrating pharmacokinetics synthesis screening, target identification and network analysis. Specifically, four parameters are used for ADME (absorption, distribution, metabolism, and excretion) screening to ensure more comprehensive first. Subsequently, the target from docking database and reference database are both retrieved to ensure the accuracy and effectiveness of the component-target (C-T) network. Ultimately, the network analysis combined with contribution score (CS) are used to elucidate the synergistic molecular actions of Zhishi-Baizhu. Hopefully, these results will provide a strategy for illuminating the therapeutic mechanism of TCM at molecular level.

![The work scheme of system pharmacology approach.](fphar-09-00841-g0001){#F1}

Methods {#s2}
=======

Chemical components database
----------------------------

All components of ZZW were collected from five publicly available natural product data sources: TCMSP database (<http://lsp.nwu.edu.cn/index.php>), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. Chemistry Database \[DB/OL\] (<http://www.organchem.csdb.cn> \[1978-2018\], Traditional Chinese Medicine integrated database (TCMID, <http://www.megabionet.org/tcmid/>), Traditional Chinese Medicine database\@Taiwan (TCM\@Taiwan, <http://tcm.cmu.edu.tw/zh-tw>), and TCM-MESH (<http://mesh.tcm.microbioinformatics.org/>). For all components, using Open Babel toolkit (version 2.4.1) to convert the initial structure formats (e.g., mol2) to the unified SDF format. Subsequently, the properties of components were retrieved from TCMSP, including molecular weight (MW), oral bioavailability (OB), Caco-2 permeability (Caco-2), drug-likeness (DL), Moriguchi octanol-water partition coefficient (LogP) (MLogP), number of acceptor atoms for H-bonds (nHAcc), number of donor atoms for H-bonds (nHDon), and topological polar surface area (TPSA), and GI absorption was retrieved from SwissADME (<http://www.swissadme.ch/index.php>).

ADME screening
--------------

In modern drug discovery, early assessment of absorption, distribution, metabolism, and excretion (ADME) screening has become an essential process. The proper use of ADME results can give preference to those drug candidates that are more likely to have good pharmacokinetic properties and minimize potential drug-drug interactions (Wang J. H. et al., [@B74]). In the present work, four ADME-related models, including OB, Caco-2, DL, and GI absorption were employed to screen the active components from ZZW (Figure [S1](#SM5){ref-type="supplementary-material"}).

OB (%F) depicts the percentage of an orally administered dose of the chemical components in herbs that reaches the systemic circulation, which displays the convergence of the ADME process. A robust *in silico* system OBioavail 1.1 (Xu et al., [@B80]) was performed to calculate the OB values of all components in ZZW. Those components with suitable OB ≥ 30% were selected as candidate components for further research.

Human intestinal cell line Caco-2 is generally employed to study the passive diffusion of drugs across the intestinal epithelium, the transport rates of components (nm/s) in Caco-2 monolayers represents the intestinal epithelial permeability in TCMSP (Ru et al., [@B58]). The Caco-2 value of the components in ZZW was obtained from TCMSP (<http://lsp.nwu.edu.cn/tcmsp.php>). Compounds with Caco-2 \> −0.4 were selected as candidate components, because components with Caco-2 \< −0.4 are not permeable.

DL is an established concept for drug design that is used to estimate which compounds have the "drug-like" prospective. The DL values of these components were calculated by the database-dependent DL evaluation approach based on Tanimoto coefficient, which is expressed as *T* (*A, B*) = (*A* × *B*)/(\|*A*\|^2^ + \|*B*\|^2^ − *A* × *B*). In this equation, A represents the molecular descriptor of herbal components, and B is the average molecular property of all components in Drugbank. The threshold of DL was set to 0.18, which is used as a selection criterion for "drug-like" compounds in the traditional Chinese herbs (Tao et al., [@B69]). During the screening process of Baizhu, we found that the DL value of lactones was lower than 0.18 but higher than 0.14, Considering lactones are the main active and characteristic compounds in BZ (China, [@B12]), so the screening criterion of Baizhu was defined as DL ≥ 0.14.

GI absorption is a pharmacokinetic behavior crucial to estimate at various stages of the drug discovery processes, which can be calculated by an accurate predictive model, IntestinaL EstimateD permeation method (BOILED-Egg) (Daina and Zoete, [@B15]). The GI absorption value of the components in ZZW was obtained from SwissADME (<http://www.swissadme.ch/index.php>) (Daina et al., [@B14]). The screening criterion of GI absorption was defined as high.

Targets identification
----------------------

To obtain the target of active components in ZZW, the commonly used databases, i.e., HitPick (Liu et al., [@B41]), Similarity Ensemble Approach (SEA) (Keiser et al., [@B29]), STITCH (Szklarczyk et al., [@B64]), and Swiss Target Prediction (Gfeller et al., [@B23]), were employed to identify the targets. All chemical structures were prepared and converted into canonical SMILES using Open Babel Toolkit (version 2.4.1). In addition, the target results were confirmed by literature reviews. Sequently, to anatomize the role of ZZW in the treatment of FD, the relationship between the obtained targets and diseases was calculated using the hypergeometric distribution algorithm: $$P_{({\text{ZZW},\ d})} = 1 - {\sum\limits_{i = 0}^{k - 1}\frac{\left( \frac{K}{i} \right)\left( \frac{N - K}{n - i} \right)}{\left( \frac{N}{n} \right)}}$$where *N* is the total number of targets in DisGeNET (Piñero et al., [@B54]), *K* is the number of targets associated with disease *d*, *n* is the quantity about the targets of ZZW, k is the number of targets shared by ZZW and disease *d*. *P*-value indicates the consequence of relevance between ZZW and disease *d* (significant when *P* \< 0.05).

Gene ontology and pathway analysis
----------------------------------

To analyze the main function of the target genes, Gene Ontology (GO) analysis was performed using the Diversity Visualization Integrated Database (DAVID 6.8) (Huang et al., [@B27]). The false discovery rate (FDR) (Dupuy et al., [@B18]) was calculated to correct the *p*-value. The criterion for difference screening was FDR \< 0.05.

The latest pathway data were obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Draghici et al., [@B17]) for KEGG pathway enrichment analyses. *P*-values were set at 0.05 as the cut-off criterion. The results of analysis were annotated by Pathview (Luo and Brouwer, [@B43]) in the R Bioconductor package (<https://www.bioconductor.org/>).

Networks construction
---------------------

The component-target network was established to find the key target. Then, the target-pathway (T-P) network was constructed to find out the relationship between the target and pathway. Cytoscape 3.5.1 (Shannon et al., [@B59]), an open-source software platform for visualizing complex networks, was employed to visualize the networks.

Contribution score calculation
------------------------------

To estimate the effect of each component of ZZW on FD treatment, we established a mathematical formula: $$A_{ij} = \ \omega_{ei} + \left| \frac{C_{Ai} + C_{Bi}}{C_{Ai} - C_{Bi}} \right|$$ $$\omega_{ei} = \frac{C_{edge}}{T_{edge}}$$ $$CS\left( i \right) = {\sum\limits_{ij}^{n}{C_{i} \times \left\lbrack {A_{ij} \times P_{j}} \right\rbrack}}$$Where *i* is the number of components and *j* is the number of proteins.

The contribution score *(CS)* represents the network contribution of one component and its effectiveness in FD. *C* represents the degree of each component, *P* represents the degree of each protein, which is calculated by Cytoscape 3.5.1. *C*~*Ai*~ represents the degree of each component only in Zhishi *C-T* network, and *C*~*Bi*~ represents the degree of each component only in Baizhu *C-T* network. *A*~*ij*~ is the index of affinity determined from the ω~*ei*~ value.

Side effect prediction
----------------------

Side effect information was obtained from SIDER, which accumulates reported side effects from package inserts for marketed drugs (Kuhn et al., [@B31]), To encode drug chemical structures, a fingerprint was used, which consisted of 61 chemical substructures defined in the PubChem database (Li et al., [@B36]). This resulted in a binary profile referred to as chemical substructure profile. The side effect prediction use the Ordinary canonical correlation analysis (OCCA) framework (Mizutani et al., [@B49]).

Statistical analysis
--------------------

To compare the molecular properties of all components in Zhishi and Baizhu, SPSS22.0 was used for statistical analysis. Data were analyzed using the student\'s *t-*test for comparison. When *P* \< 0.05, the differences were considered statistically significant.

Results {#s3}
=======

Based on a system pharmacology model, the therapeutic mechanisms of FD by ZZW were elucidated. All ZZW compounds were collected from database and literature. Next, the ADME method was used to screen for potential active components. Then related targets, disease, and pathway were identified from integrated predictive models. The obtained data were used to construct C-T and T-P networks, respectively. Finally, the CS of all compounds was calculated to illustrate the combination mechanism.

Components comparisons in zhishi and baizhu
-------------------------------------------

By a systematic search of the public databases, a total of 378 components were retrieved in Zhishi (150) and Baizhu (128). Interestingly, the species of components in Zhishi and Baizhu are different, the major components of Zhishi are flavonoids and volatile oil, whereas Baizhu is lactones and volatile oil. The detail information of these components was provided in Table [S1](#SM1){ref-type="supplementary-material"}.

To further describe the differences from the components of Zhishi and Baizhu, nine properties of these components were compared, including MW, MLogP, nHDon, nHAcc, OB, Caco-2 permeability, DL, TPSA, and GI absorption. As shown in Figure [2](#F2){ref-type="fig"}, the eight value of the components in Zhishi and Baizhu were significantly different (*P* \< 0.01) but the majority of the components did not violate Lipinski\'s rule of five (Lipinski et al., [@B39]). (1) For MW, the average value of components in Zhishi (393.39) is significantly higher than that in Baizhu (252.67) (*P* = 7.20E-15). (2) For bioavailability, the average OB value of Zhishi (28.94) is lower than that of Baizhu (37.76) (*P* = 9.72E-4). (3) For permeability, the average Caco-2 value of Zhishi (−0.20) is significally lower than that of Baizhu (0.69) (*P* = 2.26E-08). (4) For DL, unlike OB and Caco-2, Zhishi possessed higher average DL value (0.41), that is very different from that of Baizhu (0.20) (*P* = 1.58E-11). (5) Compared with the components of Zhishi (0.15), the MLogP value of Baizhu exhibited siginifically higher average MLogP value (2.10) (*P* = 7.58E-08), which indicates the majority components in Baizhu are hydrotropic, but that in Zhishi are hydrophobic. (6) The values of nHAcc, nHDon, and TPSA in Zhishi (7.67, 3.50, 51.65, respectively) are all higher than those in Baizhu (2.95, 1.54, 120.45, respectively) (6.71E-19, 1.81E-08, 1.54E-14, respectively).

![The molecular properties of all components in Zhishi and Baizhu. Molecular properties including molecular weight (MW), oral bioavailability (OB), Caco-2 permeability (Caco-2), drug-likeness (DL), Moriguchi octanol-water partition coeff. Log P (MlogP), number of acceptor atoms for H-bonds (nHAcc), number of donor atoms for H-bonds (nHDon), and topological polar surface area (TPSA). \**P* \< 0.01 by two tailed *t-*test (vs. Zhishi).](fphar-09-00841-g0002){#F2}

All the results showed that there are differences between the components of Zhishi and Baizhu, which may be due to the distinct chemo-physical properties of the components from two herbs. Our results also showed that the components from Baizhu have better pharmacokinetic properties (OB and Caco-2), whereas the components in Zhishi have better DL. Although there are obvious difference of main components between Zhishi and Baizhu, the two herbs have the identical spleen-fortifying and digestion-promoting, qi-promoting and damp-dispelling effects, which may also elucidate why Zhishi-Baizhu can produce synergistic effects.

Active components in zhishi-baizhu
----------------------------------

Even though any TCM formulation contains multiple components, only a few components possess satisfactory pharmacodynamic and pharmacokinetic properties. In the current work, four ADME-related models, including OB, Caco-2, DL, and GI, were employed to screen for active components. After ADME screening, a few components that did not meet the four screening criteria were also selected because of their high amount and high bioactive. Therefore, 61 active components were filtered out of the 378 components of ZZW. The detail information was shown in Table [1](#T1){ref-type="table"}. Additionally, we used Small Molecule Subgraph Detector (SMSD) Toolkit (Rahman et al., [@B56]) to calculate the drug similarity based on Tanimoto Coefficient, which was often used to predict Drug-drug Interations (DDIs) (Takeda et al., [@B66]), and found that in 1,891 pairs of similarity comparisons, the similarity of 1,018 pair \<=0.2, account for 54% (Figure [S3](#SM7){ref-type="supplementary-material"}). In order to calculate the potential side effect of all active compounds, we employ the OCCA framework to predict the side effects and found the slight side effects were mainly focused on agitation, weakness, and dizziness (Figure [S4](#SM8){ref-type="supplementary-material"} and Table [S4](#SM4){ref-type="supplementary-material"}).

###### 

The information of active components in ZZW.

  **ID**   **Molecule_name**                                                                                               **MW**    **OB**   **Caco-2**   **DL**   **MLOGP**   **nHAcc**   **nHDon**   **TPSA**   **GI absorption**
  -------- --------------------------------------------------------------------------------------------------------------- --------- -------- ------------ -------- ----------- ----------- ----------- ---------- -------------------
  BZ27     Atractylenolactam                                                                                               229.32    56.48    1.23         0.15     2.85        1           1           29.1       High
  BZ42     Anhydroatractylolide                                                                                            234.34    52.24    1.24         0.15     3.44        2           0           26.3       High
  BZ57     8β-methoxy-atractylenolide I                                                                                    260.33    54.47    1.02         0.19     2.63        3           0           35.53      High
  BZ59     14α-methyl butyryl-14-acetyl-2E,8E,10E-atractylentriol                                                          316.40    64.50    0.20         0.23     2.71        4           2           66.76      High
  BZ60     12α-methylbutyryl-14-acetyl-2E,8Z,10E-atractylentriol                                                           358.43    62.69    0.41         0.29     3.07        5           1           72.83      High
  BZ64     8β-ethoxyatractylenolide- II                                                                                    276.38    56.48    1.08         0.21     3.37        3           0           35.53      High
  BZ72     Isoasterolide A                                                                                                 232.32    52.65    1.27         0.15     3.35        2           0           26.3       High
  BZ75     Atractylenolide VII                                                                                             262.39    40.99    1.32         0.14     3.84        2           0           26.3       High
  BZ83     Atractylodes macrocephala                                                                                       462.68    45.96    0.85         0.81     2.47        3           1           46.53      High
  BZ84     Biatractylolide                                                                                                 462.63    45.96    0.84         0.81     5.43        4           0           52.6       High
  BZ100    8β-ethoxy atractylenolide-II                                                                                    276.38    56.48    1.08         0.21     3.37        3           0           35.53      High
  BZ102    Atractylenolide I                                                                                               230.31    35.21    1.32         0.15     3.26        2           0           26.3       High
  BZ107    Atractylone                                                                                                     216.324   25.99    1.74         0.13     3.42        1           0           13.14      High
  BZ110    AtractylenolideII                                                                                               232.32    43.54    1.31         0.15     3.35        2           0           26.3       High
  BZ119    3β-acetoxyatractylone                                                                                           274.36    34.74    1.19         0.22     2.83        3           0           39.44      High
  BZ124    14-acetyl-12-senecioyl-2E,8Z,10E-atractylentriol                                                                356.42    63.37    0.26         0.30     2.99        5           1           72.83      High
  BZ125    Atractylenolide III                                                                                             248.32    67.29    0.76         0.17     2.47        3           1           46.53      High
  ZS21     8-geranyloxypsoralen                                                                                            338.4     41.92    1.178        0.418    3.23        4           0           52.58      High
  ZS22     5-Geranyloxy-7-Methoxycoumarin                                                                                  328.4     44.23    1.121        0.300    3.16        4           0           48.67      High
  ZS23     Bergamottin                                                                                                     338.4     41.73    1.161        0.421    3.23        4           0           52.58      High
  ZS24     Phellopterin                                                                                                    300.31    37.43    0.978        0.279    1.82        5           0           61.81      High
  ZS25     Isoimperatorin                                                                                                  270.28    47.54    1.057        0.225    2.14        4           0           52.58      High
  ZS26     6′-7′-dihydroxybergamottin                                                                                      372.41    70.77    0.12         0.52     1.66        6           2           93.04      High
  ZS27     Epoxybergamottin                                                                                                354.4     57.25    0.922        0.523    2.48        5           0           65.11      High
  ZS28     Cnidilin                                                                                                        300.31    42.42    0.948        0.280    1.82        5           0           61.81      High
  ZS30     Epoxyaurapten                                                                                                   314.38    62.78    0.952        0.309    2.74        4           0           51.97      High
  ZS34     Byakangelicin                                                                                                   334.32    34.89    −0.01        0.35     0.29        7           2           102.27     High
  ZS35     Heraclenol                                                                                                      304.29    72.63    0.08         0.29     0.57        6           2           93.04      High
  ZS36     Oxypeucedanin hydrate                                                                                           304.29    33.07    −0.06        0.29     0.57        6           2           93.04      High
  ZS39     Isoponcimarin                                                                                                   330.37    63.28    0.534        0.313    1.91        5           0           69.04      High
  ZS40     Poncimarin                                                                                                      330.37    79.20    0.754        0.350    1.99        5           0           64.5       High
  ZS41     Byakangelicol                                                                                                   316.31    45.21    0.760        0.356    1.08        6           0           74.34      High
  ZS42     Oxypeucedanin                                                                                                   286.28    66.18    0.870        0.297    1.39        5           0           65.11      High
  ZS71     Monohydryoxy-tetramethoxyflavone                                                                                358.34    45.38    1.19         0.37     0.4         7           1           87.36      High
  ZS73     Diosmetin                                                                                                       300.26    42.87    0.46         0.27     0.22        6           3           100.13     High
  ZS75     5-demethylnobiletin                                                                                             388.37    89.03    1.01         0.48     0.11        8           1           96.59      High
  ZS79     Chrysoeriol                                                                                                     300.26    41.60    0.45         0.27     0.22        6           3           100.13     High
  ZS82     Sakuranetin                                                                                                     286.28    40.19    0.59         0.24     0.96        5           2           75.99      High
  ZS85     Acacetin                                                                                                        284.26    37.69    0.65         0.24     0.77        5           2           79.9       High
  ZS86     Isosakuranetin                                                                                                  286.28    37.59    0.58         0.24     0.96        5           2           75.99      High
  ZS88     N-methyl tyramine-O-alpha-L-rhamnopyranoside                                                                    297.35    36.70    −0.04        0.19     −0.16       6           4           91.18      High
  ZS104    Synephrine                                                                                                      167.21    75.25    0.63         0.04     0.65        3           3           52.49      High
  ZS105    4-\[(2S,3R)-5-\[(E)-3-hydroxyprop-1-enyl\]-7-methoxy-3-methylol-2,3-dihydrobenzofuran-2-yl\]-2-methoxy-phenol   358.39    50.76    0.03         0.39     1.09        6           3           88.38      High
  ZS107    5,7,4′-Trimethylapigenin                                                                                        312.32    39.83    1.01         0.3      1.25        5           0           57.9       High
  ZS108    Hesperetin                                                                                                      302.28    47.74    0.28         0.27     0.41        6           3           96.22      High
  ZS109    6-Methoxy aurapten                                                                                              328.4     31.24    1.01         0.3      3.16        4           0           48.67      High
  ZS110    Ammidin                                                                                                         270.28    34.55    1.13         0.22     2.14        4           0           52.58      High
  ZS115    Naringenin                                                                                                      272.26    59.29    0.28         0.21     0.71        5           3           86.99      High
  ZS117    Tetramethoxyluteolin                                                                                            342.34    43.68    0.96         0.37     0.94        6           0           67.13      High
  ZS123    Prangenin                                                                                                       286.28    43.60    0.8          0.29     1.39        5           0           65.11      High
  ZS128    Eriodyctiol (flavanone)                                                                                         288.25    41.35    0.05         0.24     0.16        6           4           107.22     High
  ZS130    Hesperidin                                                                                                      610.56    13.33    −2.03        0.67     −3.04       15          8           234.29     Low
  ZS131    Isolimonic acid                                                                                                 639.01    48.86    0.43         0.18     4.33        3           1           57.61      High
  ZS134    Isosinensetin                                                                                                   372.37    51.15    1.16         0.44     0.63        7           0           76.36      High
  ZS135    Sinensetin                                                                                                      372.37    50.56    1.12         0.45     0.63        7           0           76.36      High
  ZS137    Luteolin                                                                                                        286.24    36.16    0.19         0.25     −0.03       6           4           111.13     High
  ZS143    Naringin                                                                                                        580.53    6.92     −1.99        0.78     −2.77       14          8           225.06     Low
  ZS144    Narirutin                                                                                                       580.53    8.15     −1.8         0.75     −2.77       14          8           225.06     Low
  ZS145    Neohesperidin_qt                                                                                                302.28    71.17    0.26         0.27     0.41        6           3           96.22      High
  ZS146    Nobiletin                                                                                                       402.39    61.67    1.05         0.52     0.34        8           0           85.59      High
  ZS149    Prangenin hydrate                                                                                               304.29    72.63    0.14         0.29     0.57        6           2           93.04      High
  ZS150    Neohesperidin                                                                                                   610.62    11.57    −2.05        0.69     −3.04       15          8           234.29     Low

Active components from zhishi
-----------------------------

Through ADME screening, 44 out of 150 components were selected from Zhishi, and most of them have ideal pharmacokinetic profiles. For example, hesperetin (ZS108, OB = 47.74%, Caco-2 = 0.28, DL = 0.27, GI = high) exhibits antioxidants (de Souza et al., [@B16]), anti-inflammatory(Choi and Lee, [@B13]), and vasoprotective (Kumar et al., [@B32]) actions; Similarly, naringenin (ZS115, OB = 59.29%, Caco-2 = 0.28, DL = 0.21, GI = high) has anti-inflammatory (Manchope et al., [@B45]), antibacterial (Wang L. H. et al., [@B75]), neuroprotective(Ramakrishnan et al., [@B57]) effects. It is worth noting that the value of Caco-2 in dihydroflavonosides of Zhishi is lower, such as narirutin (ZS144), naringin (ZS143), hesperidin (ZS130), and neohesperidin (ZS150), however, the four flavonoids were the main bioactive components in Zhishi and exhibited relatively high abundances (Liu et al., [@B42]), so these components were also preserved. Especially, the value of DL in synephrine (ZS104) is low, but it is the marker components for quality control of Zhishi in Chinese Pharmacopeia (China, [@B12]). For the above reasons, 44 components were considered as potential active components of Zhishi (Table [1](#T1){ref-type="table"}).

Active components from baizhu
-----------------------------

Among 131 components in BZ, 17 components meet the screening criteria. For instance, atractylenolide I, II, III (BZ102, OB = 35.21%, Caco-2 = 1.32, DL = 0.15, GI = high; BZ110, OB = 43.54%, Caco-2 = 1.31, DL = 0.15, GI = high; BZ125, OB = 67.29%, Caco-2 = 0.76, DL = 0.17, GI = high) was the quality marker of BZ in *Chinese Pharmacopeia* (China, [@B12]) and has anti-inflammatory (Ji et al., [@B28]), anticoagulation effect (Tang et al., [@B68]) gastrointestinal repair effects (Song et al., [@B61]); Atractylenolactam (BZ27, OB = 56.48%, Caco-2 = 1.23, DL = 0.15, GI = high) exhibits anti-inflammatory activity (Hoang et al., [@B25]); Biatractylolide (BZ84, OB = 45.96%, Caco-2 = 0.84, DL = 0.81, GI = high) has a neuroprotective effect on glutamate-induced injury in PC12 and SH-SY5Y cells (Zhu et al., [@B86]). Specially, atractylone has been showed to have anti-microbial and anti-inflammatory activities (Sin et al., [@B60]), so it was also regarded to be active components. The detail information of 17 components was showed in Table [1](#T1){ref-type="table"}.

Target proteins of zhishi-baizhu
--------------------------------

To determine the relationship between the target and FD, we collected disease targets and used a hypergeometric distribution to describe the relationship probability between targets and diseases. It\'s worth noting that the target of active components is related to FD (*p* \< 0.05). In addition, the active components-related targets were further compared with all other disease in DisGeNET and the final relationship was ranked by the P value. Among the top 20 diseases, 9 were mental disorder (Figure [S2](#SM6){ref-type="supplementary-material"} and Table [S3](#SM3){ref-type="supplementary-material"}) which is one of the pathogenic factors of FD that confirmed by recent studies (Aro et al., [@B3]). Overall, most targets are related with FD, which indicated that ZZW can be used to treat FD.

To explore the therapeutic mechanism of ZZW in the treatment of FD, 61 active components and 133 targets (Table [2](#T2){ref-type="table"}) were used to construct the C-T network (Figure [3](#F3){ref-type="fig"}). Several of these active components are related multiple targets, resulting in 650 component-target associations between 61 active components and 133 targets. The average number of targets per component is 10.6, and the mean degree of components per target is 4.9, it shows that ZZW handles multi-component and multi-target characteristics of ZZW for treating FD. Acacetin (ZS85, degree = 38) has the highest number of targets, followed by luteolin (ZS137, degree = 36), chrysoeriol (ZS79, degree = 30), and 5,7,4′-Trimethylapigenin (ZS107, degree = 28), demonstrating the crucial roles of these components in the treatment of FD.

###### 

The information of the related targets of ZZW.

  **Gene**   **Protein name**                                                                 **Uniprot ID**
  ---------- -------------------------------------------------------------------------------- ----------------
  ABCB1      Multidrug resistance protein 1                                                   P08183
  ABCB4      Multidrug resistance protein 3                                                   P21439
  ABCC1      Multidrug resistance-associated protein 1                                        P33527
  ABCC2      Canalicular multispecific organic anion transporter 1                            Q92887
  ABCC3      Canalicular multispecific organic anion transporter 2                            O15438
  ABCG2      ATP-binding cassette sub-family G member 2                                       Q9UNQ0
  ABL1       Tyrosine-protein kinase ABL1                                                     P00519
  ACE        Angiotensin-converting enzyme                                                    P12821
  ACP1       Low molecular weight phosphotyrosine protein phosphatase                         P24666
  ADIPOQ     Adiponectin                                                                      Q15848
  ADORA1     Adenosine receptor A1                                                            P30542
  ADORA2A    Adenosine receptor A2a                                                           P29274
  ADORA3     Adenosine receptor A3                                                            P33765
  ADRA1A     Alpha-1A adrenergic receptor                                                     P35348
  ADRA1B     Alpha-1B adrenergic receptor                                                     P35368
  ADRA1D     Alpha-1D adrenergic receptor                                                     P25100
  ADRB1      Beta-1 adrenergic receptor                                                       P08588
  ADRB2      Beta-2 adrenergic receptor                                                       P07550
  ADRB3      Beta-3 adrenergic receptor                                                       P13945
  ALDH2      Aldehyde dehydrogenase, mitochondrial                                            P05091
  ALPI       Intestinal-type alkaline phosphatase                                             P09923
  AMY1A      Alpha-amylase 1                                                                  P04745
  AMY2A      Pancreatic alpha-amylase                                                         P04746
  AOC3       Membrane primary amine oxidase                                                   Q16853
  APP        Amyloid-beta A4 protein                                                          P05067
  AR         Androgen receptor                                                                P10275
  BCL6       B-cell lymphoma 6 protein                                                        P41182
  BDNF       Brain-derived neurotrophic factor                                                P23560
  BMP2       Bone morphogenetic protein 2                                                     P12643
  CAMK2A     Calcium/calmodulin-dependent protein kinase type II subunit alpha                Q9UQM7
  CAMK2B     Calcium/calmodulin-dependent protein kinase type II subunit beta                 Q13554
  CBR1       Carbonyl reductase \[NADPH\] 1                                                   P16152
  CCK        Cholecystokinin                                                                  P06307
  CCL11      Eotaxin                                                                          P51671
  CCL2       C-C motif chemokine 2                                                            P13500
  CCR4       C-C chemokine receptor type 4                                                    P51679
  CD80       T-lymphocyte activation antigen CD80                                             P33681
  CELA1      Chymotrypsin-like elastase family member 1                                       Q9UNI1
  CHRNA7     Neuronal acetylcholine receptor subunit alpha-7                                  P36544
  CNR1       Cannabinoid receptor 1                                                           P21554
  CNR2       Cannabinoid receptor 2                                                           P34972
  CREB1      Cyclic AMP-responsive element-binding protein 1                                  P16220
  CTSK       Cathepsin K                                                                      P43235
  CYP1A2     Cytochrome P450 1A2                                                              P05177
  CYP2C19    Cytochrome P450 2C19                                                             P33261
  CYP3A4     Cytochrome P450 3A4                                                              P08684
  DPP4       Dipeptidyl peptidase 4                                                           P27487
  DRD2       D(2) dopamine receptor                                                           P14416
  DRD3       D(3) dopamine receptor                                                           P35462
  EGFR       Epidermal growth factor receptor                                                 P00533
  ESR1       Estrogen receptor                                                                P03372
  ESR2       Estrogen receptor beta                                                           Q92731
  FAAH       Fatty-acid amide hydrolase 1                                                     O00519
  FGF2       Fibroblast growth factor 2                                                       P09038
  FOS        Proto-oncogene c-Fos                                                             P01100
  FUT4       Alpha-(1,3)-fucosyltransferase 4                                                 P22083
  GABRA3     Gamma-aminobutyric acid receptor subunit alpha-3                                 P34903
  GABRB3     Gamma-aminobutyric acid receptor subunit beta-3                                  P28472
  GABRG2     Gamma-aminobutyric acid receptor subunit gamma-2                                 P18507
  GHRL       Appetite-regulating hormone                                                      Q9UBU3
  GLO1       Lactoylglutathione lyase                                                         Q9UBU3
  GSK3B      Glycogen synthase kinase-3 beta                                                  P49841
  HDAC6      Histone deacetylase 6                                                            Q9UBN7
  HIF1A      Hypoxia-inducible factor 1-alpha                                                 Q16665
  HMOX1      Heme oxygenase 1                                                                 P09601
  HTR3A      5-hydroxytryptamine receptor 3A                                                  P46098
  IGF2R      Cation-independent mannose-6-phosphate receptor                                  P11717
  IL13       Interleukin-13                                                                   P35225
  IL2        Interleukin-2                                                                    P60568
  IL5        Interleukin-5                                                                    P05113
  IL8        Interleukin-8                                                                    P10145
  JUN        Transcription factor AP-1                                                        P05412
  KCNA3      Potassium voltage-gated channel subfamily A member 3                             P22001
  MAOA       Amine oxidase \[flavin-containing\] A                                            P21397
  MAOB       Amine oxidase \[flavin-containing\] B                                            P27338
  MAP2K7     Dual specificity mitogen-activated protein kinase kinase 7                       O14733
  MAP3K7     Mitogen-activated protein kinase kinase kinase 7                                 O43318
  MAPK8      Mitogen-activated protein kinase 8                                               P45983
  MAPT       Microtubule-associated protein tau                                               P10636
  MCL1       Induced myeloid leukemia cell differentiation protein Mcl-1                      Q07820
  MMP1       22 kDa interstitial collagenase                                                  P03956
  MMP12      Macrophage metalloelastase                                                       P39900
  MMP9       67 kDa matrix metalloproteinase-9                                                P14780
  NFKB1      Nuclear factor NF-kappa-B p105 subunit                                           P19838
  NOS1       Nitric oxide synthase, brain                                                     P29475
  NOS2       Nitric oxide synthase, inducible                                                 P35228
  NOS3       Nitric oxide synthase, endothelial                                               P29474
  NQO1       NAD(P)H dehydrogenase \[quinone\] 1                                              P15559
  NR1I2      Nuclear receptor subfamily 1 group I member 2                                    O75469
  NR4A2      Nuclear receptor subfamily 4 group A member 2                                    P43354
  ODC1       Ornithine decarboxylase                                                          P11926
  OPRD1      Delta-type opioid receptor                                                       P41143
  OPRK1      Kappa-type opioid receptor                                                       P41145
  OPRL1      Nociceptin receptor                                                              P41146
  OPRM1      Mu-type opioid receptor                                                          P35372
  PARP1      Poly \[ADP-ribose\] polymerase 1                                                 P09874
  PDE11A     Dual 3′,5′-cyclic-AMP and -GMP phosphodiesterase 11A                             Q9HCR9
  PDE4A      cAMP-specific 3′,5′-cyclic phosphodiesterase 4A                                  P27815
  PDE4D      cAMP-specific 3′,5′-cyclic phosphodiesterase 4D                                  Q08499
  PIK3CA     Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform   P42336
  PIK3CG     Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform   P48736
  PLA2G1B    Phospholipase A2                                                                 P04054
  PLAA       Phospholipase A-2-activating protein                                             Q9Y263
  PLG        Plasmin light chain B                                                            P00747
  PPARD      Peroxisome proliferator-activated receptor delta                                 Q03181
  PPARG      Peroxisome proliferator-activated receptor gamma                                 P37231
  PRKCB      Protein kinase C beta type                                                       P05771
  PRKCG      Protein kinase C gamma type                                                      P05129
  PTGS1      Prostaglandin G/H synthase 1                                                     P23219
  PTGS2      Prostaglandin G/H synthase 2                                                     P35354
  RARA       Retinoic acid receptor alpha                                                     P10276
  REL        Proto-oncogene c-Rel                                                             Q04864
  RELA       Transcription factor p65                                                         Q04206
  SHBG       Sex hormone-binding globulin                                                     P04278
  SLC6A2     Sodium-dependent noradrenaline transporter                                       P23975
  SLC6A3     Sodium-dependent dopamine transporter                                            Q01959
  SLC6A4     Sodium-dependent serotonin transporter                                           P31645
  SNCA       Alpha-synuclein                                                                  P37840
  SRD5A1     3-oxo-5-alpha-steroid 4-dehydrogenase 1                                          P18405
  STAT3      Signal transducer and activator of transcription 3                               P40763
  SYK        Tyrosine-protein kinase SYK                                                      P43405
  TACR1      Substance-P receptor                                                             P25103
  TACR2      Substance-K receptor                                                             P21452
  TACR3      Neuromedin-K receptor                                                            P29371
  TERT       Telomerase reverse transcriptase                                                 O14746
  TLR4       Toll-like receptor 4                                                             O00206
  TNFRSF1A   Tumor necrosis factor receptor superfamily member 1A                             P19438
  TNNI3      Troponin I, cardiac muscle                                                       P19429
  TP53       Cellular tumor antigen p53                                                       P04637
  TTR        Transthyretin                                                                    P02766
  VDR        Vitamin D3 receptor                                                              P11473
  VEGFA      Vascular endothelial growth factor A                                             P15692
  XDH        Xanthine dehydrogenase/oxidase                                                   P47989

![Component-target network of ZZW. The orange and purple ellipse nodes are active components of Baizhu and Zhishi, and the blue parallelogram nodes are the related targets, while the red parallelogram nodes are the same targets of Zhishi and Baizhu.](fphar-09-00841-g0003){#F3}

In Zhishi, 112 target proteins are identified for 44 active components with 538 interactions. The causes of FD mainly include dyspepsia, *Helicobacter pylori* infection, depression, etc. (Talley, [@B67]), which can generate inflammation, gastrointestinal movement dysfunction, and etc. Intriguingly, most of targets of the components in Zhishi are related to inflammation and gastrointestinal peristalsis. For instance, the three components of Zhishi, including ZS39, ZS108, and ZS143, may interact with PPARA and PPARG, which are members of a subfamily of the nuclear receptors and can modulate inflammatory responses (Varga et al., [@B72]). The other six active components, ZS71, ZS85, ZS105, ZS107, ZS128, and ZS134, were identified as interacting with PTGS1and PTGS2, also known as COX-1 and COX-2, COX-1 is a constitute engine expressed in most tissues including blood platelets and at any site of inflammation and promotes the production of natural mucus lining that protects the inner stomach, whereas COX-2 is involved in pain produced by inflammation (Mandlik et al., [@B46]). Furthermore, we have found that five components (ZS73, ZS79, ZS115, ZS117, and ZS145) are related to ABCB1 and ABCC1-3, which may critically participate in the protection of the intestinal barrier by excluding drugs, nutrients, or bacterial compounds back into the gut lumen (Langmann et al., [@B34]).

In Baizhu, 39 target proteins are identified for 17 active components with 112 interactions, including MAOA, MAOB, NOS1-3, TACR1, SLC6A4, STAT3, etc. Interestingly, majority of them are related to mental disorders and inflammation, which are confirmed associated with the pathogenesis of FD and that may be a potential therapeutic mechanism of Baizhu on FD. For example, MAOA and MAOB are the widely distributed mitochondrial enzyme with high expression levels in gastro-intestinal and hepatic as well as neuronal tissues, and are genetically associated with the pathogenesis of mental disorders (Lin et al., [@B38]); In addition, NOS1 and NOS3 can play a role in the pathogenesis and symptom of depression, NOS2 is generally up-regulated in various tissues under inflammatory conditions (Chakrabarti et al., [@B8]). Moreover, SLC6A4 is significantly related with both increased depressive symptoms and elevated IL-6 plasma levels suggesting that common phathophysiological processes may be associated with depression and inflammation (Su et al., [@B62]). It is worthy to mention that STAT3 rs2293152 polymorphism may be associated with the occurrence of ulcerative colitis and might be used as a predictive factor for ulcerative colitis (Wang et al., [@B76]). Overall, these results suggested that Zhishi and Baizhu act synergistically to treat FD by regulating inflammation, gastrointestinal peristalsis, and mental disorders.

Contribution score analysis
---------------------------

A mathematical formula was established to simulate the effect of each component of ZZW on the treatment of FD. The CS value of each active component in ZZW is calculated and showed in Figure [4](#F4){ref-type="fig"} and Table [S4](#SM4){ref-type="supplementary-material"}. According to the calculation results, the top 6 components with a sum of CS of 49.49% are acacetin (ZS85), luteolin (ZS137), chrysoeriol (ZS79), 5,7,4′-Trimethylapigenin (ZS107), diosmetin (ZS73), Tetramethoxyluteolin (ZS117), and 29 components can contribute the effects of ZZW on FD with a sum of CS of 90.18%. It has been proved that the effective therapeutic effect of ZZW on FD is derived from all active components, rather than a few components. These results may fully clarify why the herbs in ZZW could generate synergistic and combination effects on FD.

![The CS and accumulative CS of active components in ZZW.](fphar-09-00841-g0004){#F4}

Potential synergistic mechanisms analysis of zhishi and baizhu
--------------------------------------------------------------

### GO enrichment analysis for targets

GO enrichment analysis based on DAVID Functional Annotation Clustering Tool was performed to identify the biological significance of the primary target with FDR \> 0.01 and the gene count above the mean value.

In the C-T network (Figure [3](#F3){ref-type="fig"}), 37 (84%) components in Zhishi and 17 (94%) components in Baizhu have 18 same targets, including MAPT, OPRD1, OPRK1, OPRL1, OPRM1, AR, PTGS1, PTGS2, DRD2, DRD3, NOS1, NOS2, NOS3, MAOA, MAOB, ACE, SRD5A1, and SLC6A2. Surprisingly, these targets are mainly distributed in GO:0042755 eating behavior (OPRD1, OPRK1, OPRL1, OPRM1), GO:0006809 nitric oxide biosynthetic process, GO:0045909 positive regulation of vasodilation (NOS1, NOS2, NOS3), GO:0019229 regulation of vasoconstriction (ACE), GO:0042420 dopamine catabolic process (MAOA, MAOB), GO:0042417 dopamine metabolic process (DRD2, DRD3), GO:0007611 learning or memory (MAPT, DRD3, PTGS2), GO:0006954 inflammatory response (PTGS1, PTGS2), GO:0042493 response to drug (SRD5A1, SLC6A2, MAOB, DRD2, DRD3, PTGS2). Ninety percent of these GO terms are located on the related GO terms of FD. These results suggest that targets are related to FD at different levels, indicating that ZZW could produce a combination effect on FD.

In order to further dissect the combination effects of Zhishi and Baizhu, all the target interacting with the active components of Zhishi and Baizhu were enriched by GO enrichment analysis, respectively. As shown in Figure [5](#F5){ref-type="fig"}, there are six shared GO biological process (BP) terms between Zhishi and Baizhu, including oxidation-reduction process, inflammatory response, protein phosphorylation, and so on are all closely associated with FD. For instance, the oxidation-reduction process has previously been shown to correlate with the pathogenesis of depression (Grases et al., [@B24]) and inflammatory diseases of the gastrointestinal tract (such as *H. pylori* infection and IBD) (Van Hecke et al., [@B71]), and the role of inflammatory response in FD is extensive, such as anti-depression (Miller and Raison, [@B48]), eradicating H. pylori infection and improving dyspepsia (White et al., [@B77]), etc. To our surprise, 18 common gene GO terms matched only one-third of the 6 shared GO terms, this results prove once again that the treatment of ZZW for FD is a synergistic effect form.

![Go enrichment analysis of the targets of ZZW. The green part represents the shared GO terms of Zhishi and Baizhu.](fphar-09-00841-g0005){#F5}

In addition, the other 12 groups of Zhishi are also related to the treatment of FD. For instance, many investigations suggest that the regulation of cytosolic calcium ion concentration has an important role in anti-depression treatment (Yamawaki et al., [@B81]), and the abnormalities of ERK1/2 signaling may be crucial for the vulnerability of depression (Dwivedi and Zhang, [@B19]), moreover, the ERK activity constitutively or transiently may serve as a negative regulator of vascular inflammation by suppressing endothelial NF-κB activation, and play an anti-inflammatory role (Maeng et al., [@B44]). The other eight groups of Baizhu are also related to FD. For instance, patients with functional dyspepsia have a lower threshold both to the initial symptomatic recognition and to the perception of pain during gastric distension (Bradette et al., [@B5]), and depression is associated with increased platelet activation (Morel-Kopp et al., [@B51]).

Collectively, these results suggest that Zhishi and Baizhu may play synergistic and complementary effects on FD from the perspective of GO enrichment analysis.

### Pathway analysis to explore the therapeutic mechanisms of ZZW

To elaborate on the significant pathways involved in ZZW for FD therapy, all target proteins were mapped onto KEGG pathways with degree ≥ 12 (the median valve) resulting in a target-pathway (T-P) network (Figure [6](#F6){ref-type="fig"}). The T-P network contains 108 nodes (24 pathways and 84 targets and 353 edges). NFKB1, PIK3CA, RELA, MAPK8, and JUN were in the top-ranking degrees in the T-P network and linked by 19, 18, 18, 16, and 13 pathways (Figure [6](#F6){ref-type="fig"}). NFKB1 encoding pro-inflammatory cytokines, chemokines, and molecules involved in carcinogenesis was markedly up-regulated in *H. pylori* GC026-challenged cells (Castaño-Rodríguez et al., [@B7]); PIK3CA can active the PI3K signaling pathway in gastric cancer through up-regulation or mutation (Li et al., [@B37]); RELA, the principal effector of canonical NF-κB signaling (Parker et al., [@B52]); MAPK8 was mediators of signal transduction from the cell surface to the nucleus, and can regulate AP-1 transcriptional activity by multiple mechanisms (Whitmarsh and Davis, [@B78]); JUN were phosphorylated through homeodomain-interacting protein kinase 3 after cAMP stimulation (Lan et al., [@B33]). Noticeably, the target in the top-ranking degrees were almost related to FD inducing factors, such as inflammation and organisms infection, indicating that anti-inflammation and anti-microbial play a crucial role in the treatment of FD.

![Target-pathway network of ZZW. The red nodes are the common targets of Zhishi and Baizhu, and the green represents the different targets, the yellow represents the pathways. The orange area represents the depression-related pathway, the green area represents the inflammation and infection-related pathway.](fphar-09-00841-g0006){#F6}

The pathways associated with these targets showed more significant features (Figure [5](#F5){ref-type="fig"}), Neuroactive ligand-receptor interaction (hsa04080) pathway exhibits the highest number of target connections (degree = 25), followed by Calcium signaling pathway (hsa04020, degree = 19), Kaposi\'s sarcoma-associated herpesvirus infection (hsa05167, n = 19), cAMP signaling pathway (hsa04024, degree = 19), Fluid shear stress and atherosclerosis (hsa05418, degree = 16). Based on the results of pathways analysis, it was found that these high-degree pathways were closely related to neuroprotection, anti-inflammation, and anti-microbial. Specially, the crucial neuroactive ligand-receptor interaction pathway has been applied into the analysis of mental disorders (Adkins et al., [@B1]; Kong et al., [@B30]), which is regulated by 25 potential targets (ADORA1, ADORA2A, ADORA3, etc.). In addition, calcium signaling pathway is a major signal transduction, and can affect the development of some of the major psychiatric diseases such as bipolar disorder and schizophrenia by regulating neuronal excitability, information processing and cognition (Berridge, [@B4]). Nevertheless, cAMP is one of the most common and universal second messengers, and was proven that its abnormalities would be linked with psychotic depression (Perez et al., [@B53]).

In order to further explore the synergetic mechanism of Zhishi and Baizhu in the treatment of FD in ZZW, we have constructed a comprehensive pathway. As shown in Figure [7](#F7){ref-type="fig"}, in the calcium regulation center, Zhishi can act on the genes of the upstream pathway, such as ADRA1A, ADRA1B, and ADRA1D, ADORA2A, DRD2, while Baizhu can act the genes in downstream, such as PRKCB, CAMK2A, and NOS1, these results can indicate Zhishi and Baizhu play synergistic and complementary effects on learning and memory, vasodilatory, anti-inflammatory, and anti-thrombotic.

![Distribution of target proteins of ZZW on the compressed FD pathway.](fphar-09-00841-g0007){#F7}

Additionally, in the inflammation regulation center, Zhishi can act the genes of the upstream pathway, such as FGF2, BDNF, TLR4, and TNFRSF1A, while Baizhu can act the gene in the downstream pathway, such as PIK3CA, CCL2, and PTGS2, which are associated with the pathway of inflammation and synthesis of inflammatory mediators.

As the pathogenic factors of FD are related to inflammation, mental disorder, and organisms infection, so the above results suggest that Zhishi and Baizhu can exert a synergistic effect on FD at the pathway level.

Discussion {#s4}
==========

FD is a common digestive disease associated with many pathogenic factors, such as gastric and duodenal perturbations (Tack and Talley, [@B65]), organisms infection (Futagami et al., [@B22]), mental disorders (Aro et al., [@B3]), etc. The related genes of FD include NFKB1 (Castaño-Rodríguez et al., [@B7]), PIK3CA (Li et al., [@B37]), RELA (Parker et al., [@B52]), MAPK8 (Whitmarsh and Davis, [@B78]), JUN (Lan et al., [@B33]), and etc; and the involved pathway include neuroactive ligand-receptor interaction pathway (Kong et al., [@B30]), calcium signaling pathway (Berridge, [@B4]), cAMP signaling pathway (Perez et al., [@B53]), MAPK signaling pathway (Allison et al., [@B2]), NF-κB pathway (Marengo et al., [@B47]), and etc. Our study found that ZZW can treat FD by adjusting the related genes and pathways of dyspepsia, *Helicobacter pylori* infection, and depression. Thus, it is indirectly confirmed the relationship between FD and the above-mentioned pathogenic factors.

In this manuscript, we illuminate the synergistic effect of ZZW on FD from four aspects. Firstly, the C-T network showed 80 percent of the components in Zhishi and Baizhu have 18 same targets, involving GO:0042755 eating behavior, GO:0006809 nitric oxide biosynthetic process, GO:0045909 positive regulation of vasodilation, GO:0019229 regulation of vasoconstriction, GO:0042420 dopamine catabolic process, GO:0042417 dopamine metabolic process, GO:0007611 learning or memory, GO:0006954 inflammatory response, and GO:0042493 response to drug. This indicates that the herbs in ZZW have the cooperation effects on FD. Secondly, the CS of each component in ZZW are calculated and showed that 29 components can contribute the effects of ZZW for FD with a sum of 90.18% of CS. It is proved that the effective therapeutic effect of ZZW on FD is derived from all active components, not a few components. Thirdly, GO enrichment analysis indicated that all the target interacting with the active components of Zhishi and Baizhu have six shared GO BP terms, which are all closely associated with FD, whereas the 18 same targets GO terms cannot cover the shared GO terms of the target interacting with the all components, and the other components also have action, namely the components work together to play a synergistic effect. Finally, the pathway analysis proves again that Zhishi and Baizhu can exert a synergistic effect on the treatment of FD through acting the upstream and downstream gene in the calcium signaling pathway, cAMP signaling pathway, MAPK signaling pathway, and NF-κB pathway. Recent studies also established that the compatibility of Zhishi and Baizhu can promote the function of modulation of gastroinfestinal motility via regulating the levels of MTL and VIP (Li et al., [@B35]). All these results suggest that ZZW could produce a combination effect on FD.

In this study, system pharmacology and network pharmacology were used to construct a strategy for decoding the TCM pharmacologic molecular mechanism. This strategy combined physicochemical properties, network topological features, function analysis, and pathway analysis, and provided a reference for the new methods.

Currently, system pharmacology provides a powerful tool for exploring the compatibility and mechanism of TCM formulae (Yue et al., [@B82]), but its findings mainly rely on theoretical analyses, thus additional experiments are needed to validate our findings as well as potential clinical significance. It is noteworthy that the OB values of four flavanone glycoside which are the high content in Zhishi (Zeng et al., [@B83]), were \<30%. Therefore, the metabolites of these flavanone glycosides by gut microbiota may be a critical step in the emergence of their bioactivities *in vivo*, especially under the disease state (Chen F. et al., [@B9]).
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